{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T23:57:13Z","timestamp":1793145433983,"version":"4.5.0"},"reference-count":31,"publisher":"Journal of Neurosurgery Publishing Group (JNSPG)","issue":"6","license":[{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2022,12,1]]},"abstract":"<jats:sec>\n                    <jats:title>OBJECTIVE<\/jats:title>\n                    <jats:p>Clazosentan has been investigated globally for the prevention of cerebral vasospasm after aneurysmal subarachnoid hemorrhage (aSAH). The authors evaluated its effects on vasospasm-related morbidity and all-cause mortality following aSAH in Japanese patients.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>METHODS<\/jats:title>\n                    <jats:p>Two similar double-blind, placebo-controlled phase 3 studies were conducted in 57 Japanese centers in patients with aSAH, after aneurysms were secured by endovascular coiling in one study and surgical clipping in the other. In each study, patients were randomly administered intravenous clazosentan (10 mg\/hr) or placebo (1:1) starting within 48 hours of aSAH and for up to 15 days after aSAH. Stratified randomization based on World Federation of Neurosurgical Societies grade was performed using a centralized interactive web response system. Vasospasm-related morbidity and all-cause mortality within 6 weeks post-aSAH, including new cerebral infarcts and delayed ischemic neurological deficits as well as all-cause mortality, were the first primary endpoint in each study. The second primary endpoint was all-cause morbidity (new cerebral infarct or delayed ischemic neurological deficit from any causes) and all-cause mortality (all-cause morbidity\/mortality) within 6 weeks post-aSAH. The incidence of individual components of the primary morbidity\/mortality endpoints within 6 weeks and patient outcome at 12 weeks post-aSAH (including the modified Rankin Scale scores) were also evaluated. The above analyses were also performed in the population pooled from both studies.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>RESULTS<\/jats:title>\n                    <jats:p>In each study, 221 patients were randomized and 220 were included in the full analysis set of the primary analysis (109 in each clazosentan group, 111 in each placebo group). Clazosentan significantly reduced the incidence of vasospasm-related morbidity and all-cause mortality after aneurysm coiling (from 28.8% to 13.6%; relative risk reduction 53%; 95% CI 17%\u201373%) and after clipping (from 39.6% to 16.2%; relative risk reduction 59%; 95% CI 33%\u201375%). All-cause morbidity\/mortality and poor outcome (dichotomized modified Rankin Scale scores) were significantly reduced by clazosentan after preplanned study pooling. Treatment-emergent adverse events were similar to those reported previously.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>CONCLUSIONS<\/jats:title>\n                    <jats:p>Clazosentan significantly reduced the combined incidence of vasospasm-related morbidity and all-cause mortality post-aSAH with no unexpected safety findings.<\/jats:p>\n                    <jats:p>\n                      Clinical trial registration nos.: JapicCTI-163368 and JapicCTI-163369 (\n                      <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"https:\/\/www.clinicaltrials.jp\">https:\/\/www.clinicaltrials.jp<\/jats:ext-link>\n                      )\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.3171\/2022.2.jns212914","type":"journal-article","created":{"date-parts":[[2022,4,8]],"date-time":"2022-04-08T04:19:08Z","timestamp":1649391548000},"page":"1707-1717","source":"Crossref","is-referenced-by-count":131,"title":["Effects of clazosentan on cerebral vasospasm\u2013related morbidity and all-cause mortality after aneurysmal subarachnoid hemorrhage: two randomized phase 3 trials in Japanese patients"],"prefix":"10.3171","volume":"137","author":[{"given":"Hidenori","family":"Endo","sequence":"first","affiliation":[{"name":"Department of Neurosurgery, Tohoku University Graduate School of Medicine, Miyagi;"},{"name":"Department of Neurosurgery, Kohnan Hospital, Miyagi;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasushi","family":"Hagihara","sequence":"additional","affiliation":[{"name":"Department of Neurosurgery, Rinku General Medical Center, Osaka;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naoto","family":"Kimura","sequence":"additional","affiliation":[{"name":"Department of Neurosurgery, Iwate Prefectural Central Hospital, Morioka;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katsumi","family":"Takizawa","sequence":"additional","affiliation":[{"name":"Department of Neurosurgery, Japanese Red Cross Asahikawa Hospital, Hokkaido;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kuniyasu","family":"Niizuma","sequence":"additional","affiliation":[{"name":"Department of Neurosurgery, Tohoku University Graduate School of Medicine, Miyagi;"},{"name":"Department of Neurosurgical Engineering and Translational Neuroscience, Graduate School of Biomedical Engineering, Tohoku University, Miyagi;"},{"name":"Department of Neurosurgical Engineering and Translational Neuroscience, Tohoku University Graduate School of Medicine, Miyagi;"},{"name":"Research Division of Advanced Diagnosis and Treatment for Subarachnoid Hemorrhage, Tohoku University Hospital, Miyagi; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Osamu","family":"Togo","sequence":"additional","affiliation":[{"name":"Idorsia Pharmaceuticals Japan Ltd., Tokyo, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Teiji","family":"Tominaga","sequence":"additional","affiliation":[{"name":"Department of Neurosurgery, Tohoku University Graduate School of Medicine, Miyagi;"},{"name":"Research Division of Advanced Diagnosis and Treatment for Subarachnoid Hemorrhage, Tohoku University Hospital, Miyagi; and"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1754","reference":[{"issue":"10","key":"b1","series-title":"CNS Neurosci Ther","doi-asserted-by":"publisher","first-page":"1096","DOI":"10.1111\/cns.13222","article-title":"Clinical and experimental aspects of aneurysmal subarachnoid hemorrhage","volume":"25","author":"Daou BJ","year":"2019","unstructured":"Daou BJ, Koduri S, Thompson BG, Chaudhary N, Pandey AS. Clinical and experimental aspects of aneurysmal subarachnoid hemorrhage. CNS Neurosci Ther. 2019;25(10):1096\u20131112.3158383310.1111\/cns.13222"},{"issue":"1","key":"b2","series-title":"Neurosurg Rev","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1007\/s10143-006-0045-5","article-title":"Comparison between clipping and coiling on the incidence of cerebral vasospasm after aneurysmal subarachnoid hemorrhage: a systematic review and meta-analysis","volume":"30","author":"de Oliveira JG","year":"2007","unstructured":"de Oliveira JG, Beck J, Ulrich C, Rathert J, Raabe A, Seifert V. Comparison between clipping and coiling on the incidence of cerebral vasospasm after aneurysmal subarachnoid hemorrhage: a systematic review and meta-analysis. Neurosurg Rev. 2007;30(1):22\u201331.1706113710.1007\/s10143-006-0045-5"},{"issue":"1","key":"b3","series-title":"J Clin Neurosci","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1016\/0967-5868(94)90005-1","article-title":"A review of cerebral vasospasm in aneurysmal subarachnoid haemorrhage part I: incidence and effects","volume":"1","author":"Dorsch NW","year":"1994","unstructured":"Dorsch NW, King MT. A review of cerebral vasospasm in aneurysmal subarachnoid haemorrhage part I: incidence and effects. J Clin Neurosci. 1994;1(1):19\u201326.1863872110.1016\/0967-5868(94)90005-1"},{"issue":"5","key":"b4","series-title":"JAMA Neurol","doi-asserted-by":"publisher","first-page":"588","DOI":"10.1001\/jamaneurol.2019.0006","article-title":"Worldwide incidence of aneurysmal subarachnoid hemorrhage according to region, time period, blood pressure, and smoking prevalence in the population: a systematic review and meta-analysis","volume":"76","author":"Etminan N","year":"2019","unstructured":"Etminan N, Chang HS, Hackenberg K,  Worldwide incidence of aneurysmal subarachnoid hemorrhage according to region, time period, blood pressure, and smoking prevalence in the population: a systematic review and meta-analysis. JAMA Neurol. 2019;76(5):588\u2013597.3065957310.1001\/jamaneurol.2019.0006"},{"issue":"4","key":"b5","series-title":"Article in Japanese. Nihon Rinsho","first-page":"677","article-title":"Japanese Guidelines for the Management of Stroke 2015: overview of the chapter on Subarachnoid Hemorrhage","volume":"74","author":"Ishihara H","year":"2016","unstructured":"Ishihara H, Suzuki M. Japanese Guidelines for the Management of Stroke 2015: overview of the chapter on Subarachnoid Hemorrhage. Article in Japanese. Nihon Rinsho. 2016;74(4):677\u2013680.27333759"},{"key":"b6","series-title":"World Neurosurg","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1016\/j.wneu.2019.03.083","article-title":"A Review of the management of cerebral vasospasm after aneurysmal subarachnoid hemorrhage","volume":"126","author":"Li K","year":"2019","unstructured":"Li K, Barras CD, Chandra RV,  A Review of the management of cerebral vasospasm after aneurysmal subarachnoid hemorrhage. World Neurosurg. 2019;126:513\u2013527.3089874010.1016\/j.wneu.2019.03.083"},{"issue":"6163","key":"b7","series-title":"Nature","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1038\/332411a0","article-title":"A novel potent vasoconstrictor peptide produced by vascular endothelial cells","volume":"332","author":"Yanagisawa M","year":"1988","unstructured":"Yanagisawa M, Kurihara H, Kimura S,  A novel potent vasoconstrictor peptide produced by vascular endothelial cells. Nature. 1988;332(6163):411\u2013415.245113210.1038\/332411a0"},{"issue":"3","key":"b8","series-title":"J Pharmacol Exp Ther","first-page":"1110","article-title":"Ro 61-1790, a new hydrosoluble endothelin antagonist: general pharmacology and effects on experimental cerebral vasospasm","volume":"283","author":"Roux S","year":"1997","unstructured":"Roux S, Breu V, Giller T,  Ro 61-1790, a new hydrosoluble endothelin antagonist: general pharmacology and effects on experimental cerebral vasospasm. J Pharmacol Exp Ther. 1997;283(3):1110\u20131118.9399983"},{"issue":"11","key":"b9","series-title":"Stroke","doi-asserted-by":"publisher","first-page":"3015","DOI":"10.1161\/STROKEAHA.108.519942","article-title":"Clazosentan to overcome neurological ischemia and infarction occurring after subarachnoid hemorrhage (CONSCIOUS-1): randomized, double-blind, placebo-controlled phase 2 dose-finding trial","volume":"39","author":"Macdonald RL","year":"2008","unstructured":"Macdonald RL, Kassell NF, Mayer S,  Clazosentan to overcome neurological ischemia and infarction occurring after subarachnoid hemorrhage (CONSCIOUS-1): randomized, double-blind, placebo-controlled phase 2 dose-finding trial. Stroke. 2008;39(11):3015\u20133021.1868801310.1161\/STROKEAHA.108.519942"},{"issue":"7","key":"b10","series-title":"Lancet Neurol","doi-asserted-by":"publisher","first-page":"618","DOI":"10.1016\/S1474-4422(11)70108-9","article-title":"Clazosentan, an endothelin receptor antagonist, in patients with aneurysmal subarachnoid haemorrhage undergoing surgical clipping: a randomised, double-blind, placebo-controlled phase 3 trial (CONSCIOUS-2)","volume":"10","author":"Macdonald RL","year":"2011","unstructured":"Macdonald RL, Higashida RT, Keller E,  Clazosentan, an endothelin receptor antagonist, in patients with aneurysmal subarachnoid haemorrhage undergoing surgical clipping: a randomised, double-blind, placebo-controlled phase 3 trial (CONSCIOUS-2). Lancet Neurol. 2011;10(7):618\u2013625.2164065110.1016\/S1474-4422(11)70108-9"},{"issue":"6","key":"b11","series-title":"Stroke","doi-asserted-by":"publisher","first-page":"1463","DOI":"10.1161\/STROKEAHA.111.648980","article-title":"Randomized trial of clazosentan in patients with aneurysmal subarachnoid hemorrhage undergoing endovascular coiling","volume":"43","author":"Macdonald RL","year":"2012","unstructured":"Macdonald RL, Higashida RT, Keller E,  Randomized trial of clazosentan in patients with aneurysmal subarachnoid hemorrhage undergoing endovascular coiling. Stroke. 2012;43(6):1463\u20131469.2240304710.1161\/STROKEAHA.111.648980"},{"issue":"1-2","key":"b12","series-title":"Cerebrovasc Dis","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1159\/000475824","article-title":"Preventive effect of clazosentan against cerebral vasospasm after clipping surgery for aneurysmal subarachnoid hemorrhage in Japanese and Korean patients","volume":"44","author":"Fujimura M","year":"2017","unstructured":"Fujimura M, Joo JY, Kim JS, Hatta M, Yokoyama Y, Tominaga T. Preventive effect of clazosentan against cerebral vasospasm after clipping surgery for aneurysmal subarachnoid hemorrhage in Japanese and Korean patients. Cerebrovasc Dis. 2017;44(1-2):59\u201367.2846383310.1159\/000475824"},{"issue":"1","key":"b13","series-title":"Neurosurgery","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1227\/00006123-198001000-00001","article-title":"Relation of cerebral vasospasm to subarachnoid hemorrhage visualized by computerized tomographic scanning","volume":"6","author":"Fisher CM","year":"1980","unstructured":"Fisher CM, Kistler JP, Davis JM. Relation of cerebral vasospasm to subarachnoid hemorrhage visualized by computerized tomographic scanning. Neurosurgery. 1980;6(1):1\u20139.735489210.1227\/00006123-198001000-00001"},{"issue":"11","key":"b14","series-title":"J Neurol Neurosurg Psychiatry","doi-asserted-by":"publisher","first-page":"1457","DOI":"10.1136\/jnnp.51.11.1457","article-title":"A universal subarachnoid hemorrhage scale: report of a committee of the World Federation of Neurosurgical Societies","volume":"51","author":"Teasdale GM","year":"1988","unstructured":"Teasdale GM, Drake CG, Hunt W,  A universal subarachnoid hemorrhage scale: report of a committee of the World Federation of Neurosurgical Societies. J Neurol Neurosurg Psychiatry. 1988;51(11):1457.323602410.1136\/jnnp.51.11.1457"},{"issue":"10","key":"b15","series-title":"Stroke","doi-asserted-by":"publisher","first-page":"2391","DOI":"10.1161\/STROKEAHA.110.589275","article-title":"Definition of delayed cerebral ischemia after aneurysmal subarachnoid hemorrhage as an outcome event in clinical trials and observational studies: proposal of a multidisciplinary research group","volume":"41","author":"Vergouwen MD","year":"2010","unstructured":"Vergouwen MD, Vermeulen M, van Gijn J,  Definition of delayed cerebral ischemia after aneurysmal subarachnoid hemorrhage as an outcome event in clinical trials and observational studies: proposal of a multidisciplinary research group. Stroke. 2010;41(10):2391\u20132395.2079837010.1161\/STROKEAHA.110.589275"},{"issue":"3","key":"b16","series-title":"J Neurointerv Surg","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1136\/neurintsurg-2011-010248","article-title":"Invasive interventional management of post-hemorrhagic cerebral vasospasm in patients with aneurysmal subarachnoid hemorrhage","volume":"4","author":"Abruzzo T","year":"2012","unstructured":"Abruzzo T, Moran C, Blackham KA,  Invasive interventional management of post-hemorrhagic cerebral vasospasm in patients with aneurysmal subarachnoid hemorrhage. J Neurointerv Surg. 2012;4(3):169\u2013177.2237413010.1136\/neurintsurg-2011-010248"},{"key":"b17","series-title":"Drug Inf J","doi-asserted-by":"publisher","first-page":"523","DOI":"10.1177\/009286159603000228","article-title":"Statistical considerations for multiplicity in confirmatory protocols","volume":"30","author":"Koch GG","year":"1996","unstructured":"Koch GG, Gansky SA. Statistical considerations for multiplicity in confirmatory protocols. Drug Inf J. 1996;30:523\u2013533.10.1177\/009286159603000228"},{"issue":"5","key":"b18","series-title":"World Neurosurg","doi-asserted-by":"publisher","first-page":"e599","DOI":"10.1016\/j.wneu.2014.05.011","article-title":"Delayed cerebral ischemia predicts neurocognitive impairment following aneurysmal subarachnoid hemorrhage","volume":"82","author":"Stienen MN","year":"2014","unstructured":"Stienen MN, Smoll NR, Weisshaupt R,  Delayed cerebral ischemia predicts neurocognitive impairment following aneurysmal subarachnoid hemorrhage. World Neurosurg. 2014;82(5):e599\u2013e605.2484420610.1016\/j.wneu.2014.05.011"},{"issue":"6","key":"b19","series-title":"Stroke","doi-asserted-by":"publisher","first-page":"1963","DOI":"10.1161\/STROKEAHA.108.544700","article-title":"Defining vasospasm after subarachnoid hemorrhage: what is the most clinically relevant definition?","volume":"40","author":"Frontera JA","year":"2009","unstructured":"Frontera JA, Fernandez A, Schmidt JM,  Defining vasospasm after subarachnoid hemorrhage: what is the most clinically relevant definition?. Stroke. 2009;40(6):1963\u20131968.1935962910.1161\/STROKEAHA.108.544700"},{"key":"b20","series-title":"Acta Neurochir","article-title":"Development of a Delayed Cerebral Infarction load scoring system (DCI Score)","volume":"Suppl. 2020;127:145-148.","author":"Wong GKC","unstructured":"Wong GKC, Nung RCH, Sitt JCM,  Development of a Delayed Cerebral Infarction load scoring system (DCI Score). Acta Neurochir Suppl. 2020;127:145-148."},{"issue":"2","key":"b21","series-title":"Neurosurgery","doi-asserted-by":"publisher","first-page":"256","DOI":"10.1227\/NEU.0000000000001042","article-title":"Predictors of poor quality of life 1 year after subarachnoid hemorrhage","volume":"78","author":"Taufique Z","year":"2016","unstructured":"Taufique Z, May T, Meyers E,  Predictors of poor quality of life 1 year after subarachnoid hemorrhage. Neurosurgery. 2016;78(2):256\u2013264.2642159010.1227\/NEU.0000000000001042"},{"issue":"4","key":"b22","series-title":"Cochrane Database Syst Rev","first-page":"CD006184","article-title":"Antiplatelet therapy for aneurysmal subarachnoid haemorrhage","author":"Dorhout Mees SM","year":"2007","unstructured":"Dorhout Mees SM, van den Bergh WM, Algra A, Rinkel GJ. Antiplatelet therapy for aneurysmal subarachnoid haemorrhage. Cochrane Database Syst Rev. 2007;(4):CD006184."},{"issue":"2","key":"b23","series-title":"Stroke","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1161\/01.STR.31.2.383","article-title":"Effect of hypervolemic therapy on cerebral blood flow after subarachnoid hemorrhage: a randomized controlled trial","volume":"31","author":"Lennihan L","year":"2000","unstructured":"Lennihan L, Mayer SA, Fink ME,  Effect of hypervolemic therapy on cerebral blood flow after subarachnoid hemorrhage: a randomized controlled trial. Stroke. 2000;31(2):383\u2013391.10.1161\/01.STR.31.2.383"},{"issue":"11","key":"b24","series-title":"J Clin Neurosci","doi-asserted-by":"publisher","first-page":"1394","DOI":"10.1016\/j.jocn.2009.05.001","article-title":"A meta analysis of treating subarachnoid hemorrhage with magnesium sulfate","volume":"16","author":"Zhao XD","year":"2009","unstructured":"Zhao XD, Zhou YT, Zhang X, Zhuang Z, Shi JX. A meta analysis of treating subarachnoid hemorrhage with magnesium sulfate. J Clin Neurosci. 2009;16(11):1394\u20131397.1970032810.1016\/j.jocn.2009.05.001"},{"issue":"6)(suppl 1","key":"b25","series-title":"Stroke","doi-asserted-by":"publisher","first-page":"S31","DOI":"10.1161\/STROKEAHA.112.679142","article-title":"Does prevention of vasospasm in subarachnoid hemorrhage improve clinical outcome? Yes","volume":"44","author":"Macdonald RL","year":"2013","unstructured":"Macdonald RL. Does prevention of vasospasm in subarachnoid hemorrhage improve clinical outcome? Yes. Stroke. 2013;44(6)(suppl 1):S31\u2013S33.2370972210.1161\/STROKEAHA.112.679142"},{"issue":"5","key":"b26","series-title":"J Neurosurg","doi-asserted-by":"publisher","first-page":"1553","DOI":"10.3171\/2020.3.JNS193400","article-title":"Thick and diffuse cisternal clot independently predicts vasospasm-related morbidity and poor outcome after aneurysmal subarachnoid hemorrhage","volume":"134","author":"Aldrich EF","year":"2020","unstructured":"Aldrich EF, Higashida R, Hmissi A,  Thick and diffuse cisternal clot independently predicts vasospasm-related morbidity and poor outcome after aneurysmal subarachnoid hemorrhage. J Neurosurg. 2020;134(5):1553\u20131561.3244297110.3171\/2020.3.JNS193400"},{"issue":"5","key":"b27","series-title":"Eur J Heart Fail","doi-asserted-by":"publisher","first-page":"601","DOI":"10.1016\/j.ejheart.2004.05.004","article-title":"The hemodynamic and neurohormonal effects of low doses of tezosentan (an endothelin A\/B receptor antagonist) in patients with acute heart failure","volume":"6","author":"Cotter G","year":"2004","unstructured":"Cotter G, Kaluski E, Stangl K,  The hemodynamic and neurohormonal effects of low doses of tezosentan (an endothelin A\/B receptor antagonist) in patients with acute heart failure. Eur J Heart Fail. 2004;6(5):601\u2013609.1530200810.1016\/j.ejheart.2004.05.004"},{"issue":"2-3","key":"b28","series-title":"Int J Cardiol","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1016\/S0167-5273(02)00182-1","article-title":"Do results of the ENABLE (Endothelin Antagonist Bosentan for Lowering Cardiac Events in Heart Failure) study spell the end for non-selective endothelin antagonism in heart failure?","volume":"85","author":"Kalra PR","year":"2002","unstructured":"Kalra PR, Moon JC, Coats AJ. Do results of the ENABLE (Endothelin Antagonist Bosentan for Lowering Cardiac Events in Heart Failure) study spell the end for non-selective endothelin antagonism in heart failure?. Int J Cardiol. 2002;85(2-3):195\u2013197.1220858310.1016\/S0167-5273(02)00182-1"},{"issue":"2","key":"b29","series-title":"J Pharmacol Exp Ther","doi-asserted-by":"publisher","first-page":"322","DOI":"10.1124\/jpet.116.234930","article-title":"Endothelin ETA receptor blockade, by activating ETB receptors, increases vascular permeability and induces exaggerated fluid retention","volume":"361","author":"Vercauteren M","year":"2017","unstructured":"Vercauteren M, Trensz F, Pasquali A,  Endothelin ETA receptor blockade, by activating ETB receptors, increases vascular permeability and induces exaggerated fluid retention. J Pharmacol Exp Ther. 2017;361(2):322\u2013333.2822332210.1124\/jpet.116.234930"},{"issue":"5","key":"b30","series-title":"J Neurol Neurosurg Psychiatry","doi-asserted-by":"publisher","first-page":"485","DOI":"10.1136\/jnnp.2009.184960","article-title":"Validation of the Stroke Specific Quality of Life scale in patients with aneurysmal subarachnoid haemorrhage","volume":"81","author":"Boosman H","year":"2010","unstructured":"Boosman H, Passier PE, Visser-Meily JM, Rinkel GJ, Post MW. Validation of the Stroke Specific Quality of Life scale in patients with aneurysmal subarachnoid haemorrhage. J Neurol Neurosurg Psychiatry. 2010;81(5):485\u2013489.1982848010.1136\/jnnp.2009.184960"},{"key":"b31","series-title":"World Neurosurg","doi-asserted-by":"publisher","first-page":"e558","DOI":"10.1016\/j.wneu.2018.12.152","article-title":"Cognitive impairment, functional outcome, and delayed cerebral ischemia after aneurysmal subarachnoid hemorrhage","volume":"124","author":"Eagles ME","year":"2019","unstructured":"Eagles ME, Tso MK, Macdonald RL. Cognitive impairment, functional outcome, and delayed cerebral ischemia after aneurysmal subarachnoid hemorrhage. World Neurosurg. 2019;124:e558\u2013e562.10.1016\/j.wneu.2018.12.152"}],"container-title":["Journal of Neurosurgery"],"original-title":[],"link":[{"URL":"https:\/\/thejns.org\/view\/journals\/j-neurosurg\/137\/6\/article-p1707.xml","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/thejns.org\/downloadpdf\/journals\/j-neurosurg\/137\/6\/article-p1707.xml","content-type":"text\/html","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/thejns.org\/downloadpdf\/journals\/j-neurosurg\/137\/6\/article-p1707.xml","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,18]],"date-time":"2024-05-18T07:04:20Z","timestamp":1716015860000},"score":1,"resource":{"primary":{"URL":"https:\/\/thejns.org\/view\/journals\/j-neurosurg\/137\/6\/article-p1707.xml"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,12,1]]},"references-count":31,"journal-issue":{"issue":"6"},"URL":"https:\/\/doi.org\/10.3171\/2022.2.jns212914","relation":{},"ISSN":["0022-3085","1933-0693"],"issn-type":[{"value":"0022-3085","type":"print"},{"value":"1933-0693","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,12,1]]}}}